The analysis of the electronic medical records revealed that metamizole was administered in nearly one-third of the inpatient stays receiving medication (3759/11,857) within a 5-year period on paediatric general wards of a large German university hospital. This proves that metamizole is commonly used and an important substance in paediatric drug therapy, even though licensed indications are restricted in Germany and its use is still prohibited in some other European countries.
Oehme et al. [
17] compared the differences in drug exposure and ADRs at one of the general paediatric medical wards included in the present analysis between 1999 and 2008. One interesting finding was the general increase in prescription of analgesics and anti-inflammatory drugs between 1999 and 2008, especially paracetamol, ibuprofen and metamizole. The increase in antipyretic and analgesic medication was associated with a drop in antibiotic prescriptions [
17]. To our knowledge, there are no up-to-date data describing the patterns of metamizole prescriptions in a German paediatric hospital. Therefore, one of the main questions motivating this work was whether metamizole inpatient prescription patterns in children and adolescents have changed since 2008. Our study revealed slightly lower metamizole prescription rates compared with the 2008 data by Oehme et al. (39.2% [2008] vs 31.7% [2015–2020]). However, differences in the patient cohorts of the two studies need to be taken into account. The 2008 cohort only included data from one ward with the main focus on infectious disease, where more antipyretic medication is usually required. In the present study, various general paediatric wards were included besides the infectious disease ward, such as those with a focus on neuropaediatric diseases. The median age (5.0 years [2008] vs 4.9 years [2015–2020]), as well as the number of prescribed drugs per patient/case (3 drugs, each), was similar for both cohorts [
17]. In our study, the use of metamizole fluctuated from year to year in the 5-year observation period but remained in the 26–35% range in patients receiving medication during their inpatient stay. In the last observation year (06/2019–05/2020), there was a decrease in metamizole exposure and the number of hospitalised patients. This might be explained by the fact that the first lockdown of the coronavirus pandemic was imposed in March 2020. It has already been shown that the lockdown has led to a decrease in paediatric hospitalisation, in part due to a decline in communicable infectious diseases or cancellation of planned procedures [
35]. For a more detailed investigation of a possible trend, indications and the use of alternative therapy options would have to be considered. However, given these comparisons, it can be assumed that there has been no significant increase in metamizole exposure in paediatric inpatients since 2008, as has been reported for the adult population in Germany [
8].
In 2016, a survey by Witschi et al. [
1] found that 68.6% of anaesthetists (
n = 1467) use metamizole for perioperative, and 36.9% for postoperative pain treatment in children < 14 years of age. Intraoperatively, metamizole was used significantly more often compared with paracetamol and other NSAIDs [
1]. These numbers once more prove the high relevance given to metamizole in paediatrics in Germany. Besides its excellent analgesic and antipyretic efficacy, other reasons for the high metamizole use may be its low organ toxicity, therapeutic index, few contraindications, low costs, and, especially for Germany, the possible reimbursement by health insurance companies [
1,
8,
36,
37]. Another argument for metamizole use may be the reduction of opioid use after trauma surgery, which is, however, more important in the adult population [
38].
Rashed et al. [
39] showed that metamizole was the second most prescribed drug after ibuprofen in Germany. Reasons for that may be the lack of alternatives. The intravenous ibuprofen formulation was only recently licensed for patients aged from 6 years for symptomatic short-term treatment of acute moderate pain and fever when intravenous use is clinically justified and other routes of administration are not possible [
40]. Previously, intravenous ibuprofen was only licensed for ductus arteriosus occlusion in premature infants [
41], but was already used off-label as an intravenous analgesic and antipyretic drug in younger patients [
42]. Although intravenous paracetamol formulations are available and licensed for short-term treatment of moderate pain and fever [
43], there are concerns about its hepatotoxicity [
44]. Metamizole is available as intravenous formulations and is licensed from the age of 3 months [
45], which may be reasons for its popularity as a non-opioid analgesic in Germany.
Our data demonstrated that patients receiving metamizole had a statistically significant longer median length of stay than other patients. This could be partly explained by the severity of the illness of patients receiving metamizole therapy or the association with a prolonged length of stay due to a surgical procedure. However, our data also showed that the median number of days with metamizole therapy was only 2 days overall. We did not evaluate the indications in which metamizole was administered. Nevertheless, the low number of days with metamizole therapy and the high amount of parenteral use support our assumption that metamizole was only used short term and within the scope of its licence. In addition, a meta-analysis on metamizole-associated ADRs in adults concluded that short-term metamizole use in the hospital setting seems to be safe [
9]. Except for the allergic shock, in our analysis all patients with a metamizole-associated ADR had started metamizole therapy at least 14 days prior to the event. This supports the hypothesis that long-term use should be considered critically. Further studies are needed evaluating the prolonged use of metamizole.
4.3 Strengths and Limitations
To our knowledge, this is the first study evaluating metamizole drug utilisation in combination with stimulated spontaneous reporting system data in paediatric inpatients. As drug utilisation from the same hospital was already published for 1999 and 2008, we could compare metamizole exposure between the studies directly. Drug utilisation data were automatically extracted from the electronic medical records, avoiding errors due to manual transcriptions. In addition, our methodology only included the doses that were actually administered. Especially in the case of on-demand medication such as analgesics, a considerable difference can occur between the doses prescribed and those actually administered.
Our data do not reflect the picture of all inpatients, as not all wards could be included in the analysis. This is because the electronic medical record from which the prescription data were extracted was only used on general paediatric wards. Therefore, oncology, surgical or intensive care patients were not included, and no conclusions can be drawn about the frequency of metamizole use on these wards. Moreover, our data only allowed the evaluation of metamizole exposure, but not a precise characterisation of clinical use by indication and dosage. However, from clinical experience, we know that metamizole is mainly used for short-term therapy following the hospital’s standard operating procedures (SOPs), such as for ‘postoperative pain’, ‘care after PEG placement’ and ‘first aid for scald and burn’. In these SOPs, the dosage information is as follows: single doses of 10–15 mg/kg, maximum 60 mg/kg per day [
59]. Ziesenitz et al. showed that infants < 1 year of age need lower metamizole doses (5 mg/kg) to achieve equivalent adult exposure [
60].
To date, there are only a few studies combining drug utilisation with stimulated reporting system data, as we did. By doing so, the individual drug risk can only be estimated on a population level but not on an individual level. Also, combining these sources for risk estimates, one has to be very cautious as the data come from different databases and may be biased. In the present study, it is hardly possible to define the population at risk, as we only analysed the inpatient data. As agranulocytosis can appear more than 28 days after metamizole intake [
53], it could be the case that the patient has already been discharged, especially when taking into account the median length of hospital stay of 3 days (IQR 2–6) in our study. Moreover, three of our patients had taken metamizole in the ambulatory setting and are therefore not included in the utilisation data. For these reasons, calculating the reporting rate or the incidence is not possible from our point of view.